Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
1.
J Pediatric Infect Dis Soc ; 6(3): 253-259, 2017 Sep 01.
Article in English | MEDLINE | ID: mdl-26907814

ABSTRACT

BACKGROUND: Invasive pneumococcal disease (IPD) continues to be a significant burden in children despite the implementation of two generations of conjugate vaccines. Serotype replacement by nonvaccine serotypes is reported in multiple areas around the world. This study is a continuation of previous studies and describes the incidence, serotype distribution, and antibiotic resistance pattern of Streptococcus pneumoniae serotypes causing IPD at Children's Medical Center Dallas after introduction of 13-valent pneumococcal conjugate vaccine (PCV13). METHODS: Streptococcus pneumoniae isolates from normally sterile sites were collected from January 1, 1999 to June 30, 2014. Demographic and clinical information was extracted for analysis. Incidence of IPD was calculated using inpatient and emergency center admissions to Children's Medical Center of Dallas as the denominator. Isolates were serotyped and penicillin/cefotaxime susceptibilities were determined. Selected nontypeable isolates were further characterized by multilocus sequence typing. A χ2 test and the Cochran-Armitage Trend Test for trend analysis were used to evaluate change in serotype and antibiotic susceptibility patterns over time. RESULTS: Comparison of the different study periods showed a significant reduction in the incidence of IPD in PCV13 era compared with prevaccine era and PCV7 era (P < .05). Children younger than 24 months showed the largest reduction of disease incidence. More than 40% of patients with IPD had a documented comorbidity. Cases of pneumonia continued to decrease in the PCV13 era (P < .002). The most common non-PCV13 serotypes after vaccine introduction were as follows: 23B, 6C, 23A, 9N/L, and 12. Penicillin resistance by meningitis breakpoint decreased significantly in the PCV13 era. CONCLUSIONS: After introduction of PCV13 in Dallas, incidence of IPD caused by strains contained in the vaccine and penicillin resistance continued to decrease. Serotype replacement phenomena and persistence of PCV7 serotypes were documented. Patients with comorbidities represented a large percentage of patients with IPD. Concerns for geographic variation in serotype replacement phenomena arise from the present study.


Subject(s)
Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/therapeutic use , Anti-Bacterial Agents/therapeutic use , Child, Preschool , Drug Resistance, Bacterial/drug effects , Female , Humans , Infant , Male , Pneumococcal Infections/drug therapy , Serogroup , Streptococcus pneumoniae/drug effects , Vaccines, Conjugate
2.
Clin Infect Dis ; 53(7): 617-30, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21890766

ABSTRACT

Evidenced-based guidelines for management of infants and children with community-acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and investigators representing community pediatrics, public health, and the pediatric specialties of critical care, emergency medicine, hospital medicine, infectious diseases, pulmonology, and surgery. These guidelines are intended for use by primary care and subspecialty providers responsible for the management of otherwise healthy infants and children with CAP in both outpatient and inpatient settings. Site-of-care management, diagnosis, antimicrobial and adjunctive surgical therapy, and prevention are discussed. Areas that warrant future investigations are also highlighted.


Subject(s)
Community-Acquired Infections/diagnosis , Community-Acquired Infections/therapy , Pneumonia/diagnosis , Pneumonia/therapy , Child , Child, Preschool , Community-Acquired Infections/prevention & control , Humans , Infant , Pneumonia/prevention & control
3.
Clin Infect Dis ; 53(7): e25-76, 2011 10.
Article in English | MEDLINE | ID: mdl-21880587

ABSTRACT

Evidenced-based guidelines for management of infants and children with community-acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and investigators representing community pediatrics, public health, and the pediatric specialties of critical care, emergency medicine, hospital medicine, infectious diseases, pulmonology, and surgery. These guidelines are intended for use by primary care and subspecialty providers responsible for the management of otherwise healthy infants and children with CAP in both outpatient and inpatient settings. Site-of-care management, diagnosis, antimicrobial and adjunctive surgical therapy, and prevention are discussed. Areas that warrant future investigations are also highlighted.


Subject(s)
Community-Acquired Infections/diagnosis , Community-Acquired Infections/therapy , Pneumonia/diagnosis , Pneumonia/therapy , Child , Child, Preschool , Community-Acquired Infections/prevention & control , Humans , Infant , Infant, Newborn , Pneumonia/prevention & control
4.
Am J Obstet Gynecol ; 204(6): 524.e1-4, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21457910

ABSTRACT

OBJECTIVE: Women in the postpartum period are at high risk for complications from influenza. Pharmacokinetic data of oseltamivir phosphate in postpartum women, however, are lacking. STUDY DESIGN: Seven healthy patients within 48 hours of delivery were recruited. Each woman received 75 mg of oseltamivir phosphate. Plasma and breast milk samples were obtained at times 0, 0.5, 1, 2, 4, 8, 12, and 24 hours after the first dose. The samples were analyzed for oseltamivir and oseltamivir carboxylate levels. Using a noncompartmental model, area under the curve (AUC), maximum concentration (C(max)), time to maximum concentration, and half-life were estimated. RESULTS: Oseltamivir phosphate and oseltamivir carboxylate were found in breast milk, although later and in lower levels than that found in plasma. The C(max) and AUC 0-24 was higher for the active metabolite than for the prodrug in both plasma and breast milk. CONCLUSION: Oseltamivir carboxylate was present in breast milk but in concentrations significantly lower than considered therapeutic in infants.


Subject(s)
Antiviral Agents/blood , Antiviral Agents/pharmacokinetics , Milk, Human/chemistry , Oseltamivir/blood , Oseltamivir/pharmacokinetics , Female , Humans , Postpartum Period , Young Adult
5.
Am J Obstet Gynecol ; 204(6 Suppl 1): S89-93, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21492824

ABSTRACT

The purpose of this study was to determine pharmacokinetic parameters for oseltamivir in all trimesters of pregnancy. Thirty pregnant women, 10 per trimester, who were receiving oseltamivir phosphate (75 mg) were recruited to study first-dose pharmacokinetics. Plasma samples were obtained at 0, 0.5, 1, 2, 4, 8, and 12 hours after the first dose. Samples were analyzed for oseltamivir and oseltamivir carboxylate levels. With the use of a noncompartmental model, we estimated the area-under-the-curve, maximum concentration, time-to-maximum concentration, and half-life. There were no significant differences in the pharmacokinetics of oseltamivir by trimester, except for an increased half-life in the first trimester for oseltamivir phosphate and an increased maximum concentration in the third trimester for oseltamivir carboxylate. The levels of oseltamivir carboxylate that were observed were within the range that was needed to achieve inhibitory concentrations at 50% for pandemic H1N1. The pharmacokinetics of oseltamivir does not change significantly according to trimester of pregnancy.


Subject(s)
Antiviral Agents/pharmacokinetics , Influenza A Virus, H1N1 Subtype , Influenza, Human/drug therapy , Oseltamivir/pharmacokinetics , Pregnancy Complications, Infectious/drug therapy , Pregnancy Trimesters/blood , Adolescent , Adult , Antiviral Agents/blood , Area Under Curve , Female , Half-Life , Humans , Influenza A virus , Influenza B virus , Influenza, Human/blood , Influenza, Human/epidemiology , Maximum Allowable Concentration , Oseltamivir/analogs & derivatives , Oseltamivir/blood , Pandemics , Pregnancy , Pregnancy Complications, Infectious/blood , Pregnancy Complications, Infectious/epidemiology , Time Factors , Young Adult
6.
Pediatr Infect Dis J ; 29(6): 519-23, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20051928

ABSTRACT

BACKGROUND: Respiratory viruses contribute to the seasonal pattern of invasive pneumococcal disease (IPD), but the impact of viral coinfections on the clinical characteristics and outcomes of patients with IPD have not been well defined. OBJECTIVE: This study was designed to describe and compare the clinical presentations and outcomes of patients with IPD with or without viral coinfections. DESIGN/METHODS: Retrospective analyses of records of all children treated at Children's Medical Center Dallas (CMCD) for IPD from July 2005 to June 2008. Viral studies included viral direct fluorescent antibody staining and culture. For comparisons, patients were classified in 3 groups: with positive, negative, and no viral studies performed. RESULTS: A total of 129 patients were admitted to CMCD with IPD during the 3 year study; 57% were male. Ages ranged from 2 months to 18 years (median 25 months) and 48% were <2 years. Viral studies were performed in 82 (63%) patients, and 28 (34%) had positive results. The most common viruses isolated were influenza (7, 25%), rhinoviruses (6, 21%), adenoviruses (6, 21%), and RSV (5, 18%). Peaks of positive viral studies occurred in February and November which coincided with the peak numbers of patients admitted with IPD. Of 6 with adenovirus coinfection, 5 were admitted to Pediatric Intensive Care Unit (PICU). The most common pneumococcal serotypes were 19A (41, 32.5%), 7F (14, 11%), and 23A (13, 10.3%). Pneumonia (42%), bacteremia (22%), and meningitis (17%) were the most common clinical syndromes. There were no differences in duration of fever before admission, maximum temperatures during hospitalization and white blood cell counts, duration of fever and hospitalization between patients with positive and negative viral studies, but there was a trend for patient with positive viral studies to be admitted to PICU more frequently and to have longer PICU stay. Three of the 6 patients who died had documented viral coinfections (2 adenovirus, 1 parainfluenza 3), and all 3 had no underlying conditions. The other 3 patients who died had no viral studies performed. Duration of treatment ranged from 1 to -210 days (median 14), with no differences among the groups. CONCLUSIONS: Viral coinfections were common in children with IPD. Future prospective studies should include new PCR assays to characterize better the impact of viral coinfections in the occurrence and outcome of IPD.


Subject(s)
Adenoviridae Infections/microbiology , Pneumococcal Infections/virology , RNA Virus Infections/microbiology , Respiratory Tract Diseases/microbiology , Respiratory Tract Diseases/virology , Adenoviridae , Adenoviridae Infections/epidemiology , Adenoviridae Infections/virology , Adolescent , Analysis of Variance , Chi-Square Distribution , Child , Child, Preschool , Female , Humans , Infant , Male , Pneumococcal Infections/epidemiology , Pneumococcal Infections/microbiology , RNA Virus Infections/epidemiology , RNA Virus Infections/virology , RNA Viruses , Respiratory Tract Diseases/epidemiology , Retrospective Studies , Statistics, Nonparametric , Streptococcus pneumoniae/isolation & purification , Texas/epidemiology
7.
Pediatr Infect Dis J ; 29(4): 294-300, 2010 Apr.
Article in English | MEDLINE | ID: mdl-19949357

ABSTRACT

BACKGROUND: The heptavalent pneumococcal conjugate vaccine (PCV7) has significantly reduced vaccine-type invasive pneumococcal disease (IPD) in children. An increasing percentage of IPD cases are now caused by nonvaccine serotypes. The purpose of our observational study was to define the epidemiology of pneumococcal disease in Dallas, TX children for 8 years after implementation of PCV7 immunization. METHODS: Streptococcus pneumoniae isolates from normally sterile sites were collected at Children's Medical Center of Dallas from January 1, 1999 to December 31, 2008. Incidence of IPD was calculated using inpatient and emergency center admissions to Children's Medical Center of Dallas as the denominator. Isolates were serotyped and penicillin and cefotaxime susceptibilities were determined. Serotype 19A isolates were further characterized by multilocus sequence typing. RESULTS: Compared with the prevaccine period of 1999-2000, there was a significant reduction in the incidence of IPD from 2002 to 2008 (P < 0.05), although a significant increase in IPD incidence was observed from 2006 to 2008 (P = 0.038). The number of IPD cases caused by serotype 19A increased from 1999 to 2008 (P < 0.001). There were significant increases in penicillin and cefotaxime nonsusceptible 19A isolates during this 10-year period (P < 0.001 and P = 0.004, respectively). The most common sequence type (ST) of the 19A isolates was ST-199 (42.7%). Clonal complex (cc-156) and cc-320 emerged in the period of 2005-2008 as penicillin and cefotaxime resistant 19A strains. CONCLUSIONS: In Dallas, PCV7 immunization reduced significantly the incidence of IPD caused by vaccine-type strains. A significant increase in IPD caused by serotype 19A was observed. The penicillin and cefotaxime nonsusceptible STs, not previously identified in Dallas, have recently become an important cause of IPD.


Subject(s)
Drug Resistance, Multiple, Bacterial , Pneumococcal Infections/epidemiology , Pneumococcal Vaccines , Program Evaluation , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/drug effects , Anti-Bacterial Agents/pharmacology , Cefotaxime/pharmacology , Child, Preschool , Female , Heptavalent Pneumococcal Conjugate Vaccine , Humans , Immunization Programs , Incidence , Infant , Male , Microbial Sensitivity Tests , Penicillins/pharmacology , Pneumococcal Infections/microbiology , Pneumococcal Infections/prevention & control , Pneumococcal Vaccines/administration & dosage , Pneumococcal Vaccines/immunology , Serotyping , Streptococcus pneumoniae/immunology , Streptococcus pneumoniae/isolation & purification , Texas/epidemiology
10.
Pediatr Pulmonol ; 44(2): 148-54, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19137597

ABSTRACT

UNLABELLED: Alternative antimicrobial regimens are needed for treatment of methicillin-resistant Staphylococcus aureus (MRSA)-associated pulmonary exacerbations in children with cystic fibrosis (CF). There are no published pharmacokinetic (PK) and pharmacodynamic (PD) data for linezolid in children with CF. OBJECTIVES: (1) To determine the PK and PD profile of linezolid among children with CF; (2) to characterize the effect of linezolid on MRSA infection; (3) to determine the effect of age and CF transmembrane regulator (CFTR) gene mutations on drug clearance. HYPOTHESES: Linezolid clearance is enhanced in children with CF requiring a higher dosage regimen. Age and CFTR gene mutations affect drug clearance. METHODS: This was a retrospective cohort study; medical records of children with MRSA-associated pulmonary exacerbations treated with linezolid (10 mg/kg/dose IV every 8h) were reviewed. Linezolid peak and trough concentrations in serum were determined by high performance liquid chromatography, PK profiles determined using standard noncompartmental method, and PD indices were evaluated. RESULTS: 10 children (mean +/- SD, 10.2 +/- 5.5 years) received 14 courses of linezolid at 10 +/- 0.4 mg/kg/dose every 8h for 15.4 +/- 3.2 days. Seven had homozygous DeltaF508 CFTR mutation. Peak and trough linezolid concentrations varied widely (range, 8.4-20.5 and 0.1-11.5 mcg/mL respectively). The PK profile of children <10 years differed significantly from older patients (>or=10 years). The PK indices of children with homozygous DeltaF508 differed marginally from those with heterozygous CFTR mutations, but there were too few subjects to allow separation of age and CFTR mutations effect. No patient achieved the target PD ratio of AUC/MIC >80. MRSA persisted in sputum or throat culture after treatment with linezolid. CONCLUSIONS: Additional PK and PD data are needed to optimize linezolid therapy in children with cystic fibrosis; it is likely that higher doses will be needed.


Subject(s)
Acetamides/pharmacokinetics , Anti-Infective Agents/pharmacokinetics , Cystic Fibrosis/drug therapy , Methicillin-Resistant Staphylococcus aureus/drug effects , Oxazolidinones/pharmacokinetics , Acetamides/administration & dosage , Acetamides/therapeutic use , Adolescent , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/therapeutic use , Child , Child, Preschool , Cystic Fibrosis Transmembrane Conductance Regulator , Female , Humans , Linezolid , Male , Oxazolidinones/administration & dosage , Oxazolidinones/therapeutic use , Retrospective Studies
11.
Clin Infect Dis ; 47 Suppl 3: S241-8, 2008 Dec 01.
Article in English | MEDLINE | ID: mdl-18986297

ABSTRACT

There are few placebo-controlled, randomized, prospective clinical trials of antibiotic therapy for community-acquired pneumonia (CAP) in children. The reduction in mortality seen in early trials of antibacterials for treatment of bacterial CAP in adults and children was dramatic and led to the adoption of antibacterial therapy as the standard of care for CAP in both adults and children. Because of the efficacy of antibacterials for treatment of CAP in adults and the reluctance of society to place children at risk of adverse outcomes in placebo-controlled clinical trials, pediatric investigations of this type were not performed after 1940. Instead, comparative trials were subsequently conducted and reported. More recently, comparative trials using a noninferiority trial design have been used by regulatory agencies to grant approval of antibiotic therapy for pediatric CAP. We cannot reliably distinguish between pneumonia cases caused by bacterial, viral, or atypical pathogens among the relatively homogeneous population of children with CAP who are enrolled into clinical trials. Patient- or parent-reported outcomes represent an option for appropriate, defined clinical trial outcomes for pediatric CAP, because the disease in children has a relatively short and potentially self-resolving clinical course. Clinical trials that require invasive techniques for diagnosis and placebo-controlled randomized trials are not acceptable for children, who are considered to be a vulnerable population.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Clinical Trials as Topic , Community-Acquired Infections/drug therapy , Pneumonia/drug therapy , Adult , Child , Child, Preschool , Humans , Infant , Treatment Outcome
12.
Pediatr Infect Dis J ; 26(12): 1128-32, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18043450

ABSTRACT

BACKGROUND: Clinical improvement is often delayed among children with invasive infections caused by multidrug resistant Gram-positive bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) despite use of standard antimicrobial therapy. Daptomycin, a bactericidal lipopeptide antibiotic, may prove useful for treatment of these infections in children, but clinical experience is lacking. METHODS: Retrospective review of medical records of hospitalized children who received daptomycin for treatment of invasive Gram-positive bacterial infections at Children's Medical Center Dallas from December 2003 to March 2007. Bacterial isolates were tested for susceptibility to daptomycin and characterized by pulsed-field gel electrophoresis and polymerase chain reaction for staphylococcal cassette chromosome mec A. RESULTS: Sixteen children (10 male; median age, 6.5 years) received daptomycin. Fifteen (94%) children had invasive staphylococcal disease (14, MRSA, of which 13 were community-associated; 1, methicillin-susceptible S. aureus), and 1 had urinary tract infection caused by VRE. Twelve children with disseminated staphylococcal disease had bacteremia for 2-10 days despite therapy with 2 or more of the following: vancomycin, clindamycin, rifampin, aminoglycoside, or linezolid. The addition of daptomycin resulted in bacteriologic cure in 6 of 7 evaluable patients with persistent bacteremia. No adverse events were attributed to daptomycin. Overall, 14 patients improved and were discharged home, and 2 died of complications of their underlying medical conditions. CONCLUSIONS: The majority of patients demonstrated clinical improvement after addition of daptomycin to conventional antimicrobial therapy. Further studies are needed to assess the pharmacokinetics, pharmacodynamics, safety, and effectiveness of daptomycin in infants and children.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Daptomycin/therapeutic use , Gram-Positive Bacterial Infections/drug therapy , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/adverse effects , Bacteremia/drug therapy , Bacteremia/microbiology , Child , Daptomycin/administration & dosage , Daptomycin/adverse effects , Drug Therapy, Combination , Enterococcus faecium/drug effects , Female , Gram-Positive Bacterial Infections/microbiology , Hospitalization , Humans , Male , Methicillin/pharmacology , Methicillin Resistance/genetics , Staphylococcal Infections/drug therapy , Staphylococcal Infections/microbiology , Staphylococcus aureus , Treatment Outcome , Vancomycin Resistance
14.
Pediatr Pulmonol ; 42(7): 640-5, 2007 Jul.
Article in English | MEDLINE | ID: mdl-17534977

ABSTRACT

OBJECTIVES: Characterization of the systemic cytokine response in community-acquired pneumonia (CAP) may facilitate our understanding of the host immune response and provide a prognostic as well as diagnostic tool. Systemic cytokine characterization of CAP has been limited largely to a few integral cytokines in adults. METHODS: Analyses were performed to investigate whether significant relationships existed between an expanded serum cytokine profile and etiologies, manifestations, and outcomes of pediatric CAP. The serum concentrations of 15 cytokines were investigated in 55 hospitalized children with well-characterized CAP. RESULTS: Comparison of median cytokine concentrations among patients with CAP caused by Mycoplasma pneumoniae or Chlamydophila pneumoniae, Streptococcus pneumoniae, viruses, mixed infections, or unidentified pathogens revealed significant differences in IFN-alpha, IL-6, IL-17, GM-CSF, and TNF-alpha concentrations. The mixed infections category had significantly elevated concentrations of IFN-alpha, IL-6, GM-CSF, and TNF-alpha. There were significant correlations between concentrations of IL-6 and markers of disease severity (white blood cell band-forms, procalcitonin, and unequivocal consolidation). No single cytokine could reliably differentiate the etiologic cause of pneumonia. CONCLUSIONS: IL-6 is the only one of 15 serum cytokines studied that correlated with indicators of disease severity in childhood CAP. The applicability of cytokine profiles to identify microbiologic etiologies of pneumonia remains to be defined.


Subject(s)
Cytokines/blood , Pneumonia/blood , Child , Child, Preschool , Community-Acquired Infections/blood , Community-Acquired Infections/diagnosis , Community-Acquired Infections/etiology , Community-Acquired Infections/immunology , Female , Humans , Infant , Male , Pneumonia/diagnosis , Pneumonia/immunology , Pneumonia/microbiology
15.
Pediatr Infect Dis J ; 26(6): 461-7, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17529859

ABSTRACT

BACKGROUND: Because the heptavalent pneumococcal conjugate vaccine has reduced vaccine-type invasive pneumococcal disease (IPD) in children, a greater proportion of IPD is now caused by nonvaccine (NVT) serotypes. We analyzed the serotypes, antimicrobial resistance profiles and genetic relatedness of Streptococcus pneumoniae responsible for IPD at Children's Medical Center of Dallas. METHODS: S. pneumoniae isolates were collected from January 1, 1999 through December 31, 2005. Incidence of IPD was calculated using inpatient and emergency center admissions to Children's Medical Center of Dallas as the denominator. Isolates were serotyped, and their penicillin and cefotaxime susceptibility determined. The 19A isolates were further characterized by pulsed-field gel electrophoresis, multilocus sequence typing and determination of penicillin-binding proteins and mef and erm genes. RESULTS: The incidence of IPD decreased from 93.6 cases/100,000 patients in 1999 to a nadir of 41 cases/100,000 patients in 2003 (P < 0.001). The number of IPD cases caused by serotype 19A increased, accounting for 40% of the cases of IPD in 2005. Penicillin and cefotaxime susceptibility of IPD isolates did not change from 1999 through 2005 (P = 0.687). There was a decrease in penicillin (P < 0.001) and cefotaxime (P = 0.034) susceptibility in NVT serotypes from 1999 to 2005. Molecular characterization of 19A isolates revealed a predominance of ST-199 (62%). Several highly penicillin-resistant and intermediately cefotaxime-resistant strains emerged in 2004 and 2005. CONCLUSIONS: In Dallas, heptavalent pneumococcal conjugate vaccine reduced the incidence of IPD from 1999 to 2005 by reducing the incidence of vaccine-type disease. NVT serotypes, particularly 19A, were prevalent and more resistant to antimicrobials in 2004 and 2005.


Subject(s)
Drug Resistance, Bacterial , Meningococcal Vaccines/immunology , Pneumococcal Infections/immunology , Pneumococcal Infections/microbiology , Pneumococcal Vaccines/immunology , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/drug effects , Adolescent , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , Cefotaxime/pharmacology , Child , Child, Preschool , DNA Fingerprinting , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Electrophoresis, Gel, Pulsed-Field , Female , Heptavalent Pneumococcal Conjugate Vaccine , Humans , Incidence , Infant , Male , Membrane Proteins/genetics , Methyltransferases/genetics , Microbial Sensitivity Tests , Penicillins/pharmacology , Pneumococcal Infections/epidemiology , Serotyping , Streptococcus pneumoniae/immunology , Streptococcus pneumoniae/isolation & purification , Texas/epidemiology
16.
Ann Allergy Asthma Immunol ; 97(4): 457-63, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17069099

ABSTRACT

BACKGROUND: Clarithromycin is postulated to possess immunomodulatory properties in addition to its antimicrobial activity. OBJECTIVE: To evaluate the effect of clarithromycin on serum and nasopharyngeal cytokine and chemokine concentrations in children with an acute exacerbation of recurrent wheezing. METHODS: Children with a history of recurrent wheezing or asthma and who presented with an acute exacerbation of wheezing were enrolled in a double-blind, randomized trial of clarithromycin vs placebo. Concentrations of tumor necrosis factor alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin-1beta (IL-1beta), IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, granulocyte-macrophage colony-stimulating factor, RANTES, eotaxin, macrophage inflammatory protein 1alpha, macrophage inflammatory protein 1beta, and monocyte chemoattractant protein 1 were measured in serum and/or nasopharyngeal aspirates before, during, and after therapy. Mycoplasma pneumoniae and Chlamydophila pneumoniae infection were evaluated for by polymerase chain reaction and serologic testing. RESULTS: Nasopharyngeal concentrations of TNF-alpha, IL-1beta, and IL-10 were significantly and persistently lower in children treated with clarithromycin compared with placebo. There tended to be a greater effect of clarithromycin on nasopharyngeal cytokine concentrations in patients with evidence of M. pneumoniae or C. pneumoniae infection. No significant differences were detected in serum cytokines for children treated with clarithromycin compared with placebo. CONCLUSION: Clarithromycin therapy reduces mucosal TNF-alpha, IL-1beta, and IL-10 concentrations in children with an acute exacerbation of recurrent wheezing.


Subject(s)
Asthma/drug therapy , Chemokines/blood , Clarithromycin/therapeutic use , Cytokines/blood , Respiratory Sounds/drug effects , Acute Disease , Adolescent , Asthma/blood , Asthma/immunology , Bronchoalveolar Lavage Fluid/immunology , Child , Child, Preschool , Double-Blind Method , Female , Humans , Male , Placebos , Recurrence , Respiratory Sounds/immunology
17.
Int J Antimicrob Agents ; 28(3): 253-8, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16891098

ABSTRACT

Mycoplasma pneumoniae infection has been associated with chronic lung disease. Treatment of chronic pulmonary mycoplasmosis has not been well investigated. BALB/c mice were intranasally inoculated once with M. pneumoniae or with sterile media (uninfected controls). Infected mice were treated with telithromycin or placebo daily for 10 days in the chronic phase of disease (18 months after inoculation). Mice (n=43) were evaluated before therapy and 1 day after completion of telithromycin. Treatment of infected mice with telithromycin at 18 months after infection significantly reduced chronic pulmonary histological inflammation compared with infected mice given placebo; however, this treatment did not improve airway obstruction or airway hyperresponsiveness. Therapy longer than 10 days may be necessary to improve pulmonary function.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Ketolides/therapeutic use , Mycoplasma pneumoniae/drug effects , Pneumonia, Mycoplasma/drug therapy , Animals , Chronic Disease , Disease Models, Animal , Female , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , Plethysmography , Pneumonia, Mycoplasma/pathology , Pneumonia, Mycoplasma/physiopathology
18.
Pediatr Infect Dis J ; 25(3): 208-10, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16511381

ABSTRACT

BACKGROUND: Of several oral cephalosporins, cefdinir is recommended as an alternative therapy for children with acute otitis media who have type 1 hypersensitivity to beta-lactams. Because the current cefdinir dosage of 14 mg/kg/d is approved for treatment of acute otitis media caused by penicillin-susceptible Streptococcus pneumoniae, we hypothesized that a 25-mg/kg dose given daily would be more effective for nonsusceptible S. pneumoniae. METHODS: We performed pharmacokinetic analyses on 37 infants and children who were given cefdinir in dosages of 14 or 25 mg/kg once daily for 10 days, for the treatment of respiratory and skin or skin structure infections. Cefdinir plasma concentrations were determined with validated liquid chromatology, and pharmacokinetics and pharmacodynamics were determined in relation to the minimum inhibitory concentration values of S. pneumoniae. RESULTS: The maximal plasma concentrations and area-under-the-curve values were significantly higher after the 25-mg/kg in relation to the minimum inhibitory concentration values for S. pneumoniae strains. The pharmacodynamics measure of bacteriologic effectiveness was <40% of the dosing interval (ie, 24 hours), indicating that many of the penicillin-nonsusceptible S. pneumoniae causing acute otitis media would not be effectively treated. Diarrhea occurred in 20% of the 39 subjects that received the larger dosage of cefdinir. CONCLUSION: A cefdinir dosage of 25 mg/kg daily would be ineffective for treatment of acute otitis media caused by penicillin-nonsusceptible S. pneumoniae strain.


Subject(s)
Anti-Infective Agents , Cephalosporins , Pneumococcal Infections/drug therapy , Respiratory Tract Infections/drug therapy , Acute Disease , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/adverse effects , Anti-Infective Agents/pharmacokinetics , Cefdinir , Cephalosporins/administration & dosage , Cephalosporins/adverse effects , Cephalosporins/pharmacokinetics , Child , Child, Preschool , Humans , Infant , Microbial Sensitivity Tests , Otitis Media/drug therapy , Otitis Media/microbiology , Penicillin Resistance , Pneumococcal Infections/microbiology , Respiratory Tract Infections/microbiology , Soft Tissue Infections/drug therapy , Soft Tissue Infections/microbiology , Streptococcus pneumoniae/drug effects , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...